Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs
/in Dendritic Cells, International PublicationsStimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70
/in Hyperthermia, International PublicationsIdiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines
/in Dendritic Cells, International Publications, Multiple MyelomaPostirradiation malignant fibrous histiocytoma of the larynx: a case report
/in Dendritic Cells, International Publications, Newcastle Disease Virus[Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?]
/in Hyperthermia, International Publications, Pancreatic CancerWhole-body hyperthermia: a review of theory, design and application
/in Hyperthermia, International PublicationsHuman tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease VirusVaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer
/in Cervical Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer